Global HIV Diagnostics Market
Acquired immune deficiency syndrome (AIDS) is a retroviral infectious disease caused by human immunodeficiency virus (HIV). HIV attacks the body immune system ideally CD4 cells (T cells), which helps the immune system to fight infections. HIV spreads through body fluids i.e. blood donation and imparting needles to somebody who is HIV infected, and sexual interactions. If HIV is not treated the opportunistic infections like tuberculosis or cancer take advantage of very weak immune system and causes AIDS. The HIV diagnosis can be done by viral load test, saliva test, and blood test. Most accurate test results can obtained by enzyme linked immunosorbent assay (ELISA) test initial stages and western blot method on later stages. Currently, there was no effective cure exists for HIV, but with proper medical care, it can be controlled.
HIV diagnostics market is driven by global increase in prevalence of HIV/AIDS, rise in number of blood transfusions and blood donations, benefits of point-of-care instruments & kits in which patients can be diagnosed even outside the laboratory setting, and increasing government initiatives. In addition, technological advancements in disease diagnostic tests, improvement and commercialization of novel, regulatory approved point of care and rapid CD4, p24 antigen and EID tests are expected to boost the HIV diagnostics market over the forecast period. However, lack of awareness in many undeveloped regions, stringent government regulations and unfavourable reimbursement policies would limit the growth of the market.
HIV Diagnostics Market segmented based on type of test, and end user
Based on type of test, HIV diagnostics market is segmented into
- CD4 Count
- Antibody Test
- Viral Identification
- Viral Load
Based on end-user, HIV diagnostics market is segmented into
- Diagnostic Centers
- Blood Banks
- Home Care Settings
Global HIV diagnosis market is growing at steady state. Government and non-government organizations are also participating in creating and growing awareness related to early HIV diagnosis and available diagnostic tests and equipment. According to WHO, 2015, there is 0.8% prevalence of HIV globally and Sab-Saharan Africa remains most severely affected area with 70% of people for global population. For instance, the unmet requirements in Asia and Africa region for HIV diagnosis, and the government initiatives taken in the region may drive the market for HIV diagnostics. Market players adopting mergers and acquisitions to increase the market position in HIV diagnostics market. In addition, market has a number of pipeline products in accurate and quick diagnosis of HIV few of them are Visitect CD4, Chipcare CD4, and MBIO CD4. Antibody diagnosis test is predominant among the segments. Due to the introduction of point of care products can easily and quickly diagnose disease.
Geographically HIV diagnostics market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds dominant revenue share in global HIV diagnostics market, and it is due to rapid adoption of technologically, advanced diagnostic solutions, and growing demand for portable and point of care (POC) diagnostic devices. Furthermore, large pool of patients suffering with HIV and mandatory implementation of HIV screening tests are expected to boost regional penetration of HIV diagnostics. As per the WHO statistics, by the end of 2011, 1.4 Mn people were infected with HIV/AIDS including adults and children. Asia-Pacific expected to be lucrative market for HIV diagnostics, owing to growing patients suffering from HIV/AIDS and increase in awareness among the population related to HIV diagnostics. In the Middle East and Africa region, South Africa has enormous opportunity due to increasing awareness and presence of a large number of infected people. According to UNAIDS report, 2016, 19.4 Mn people in Eastern and South Africa alone living with HIV, and it is more than half of the HIV infected people around the world.
Some of the players in HIV diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Siemens Healthineers) (Germany), Merck KGaA (Germany) Hologic, Inc. (U.S.), Fisher Bioblock Holding II SNC (Thermo-Fisher Scientific) (U.S.),Becton, Dickinson and Company (U.S.),Alere Inc. (U.S.), and Bio-Rad Laboratories (U.S.) to name a few.
- In 2015, bioLytical Laboratories Inc., a leading manufacturer of point-of-care rapid diagnostic tests, received U.S. Food and Drug Administration (FDA) approval of its INSTI HIV Antibody Test for use in detecting antibodies to HIV type 2
- The report provides granular level information about the market size, regional market share and forecast from 2017-2024
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario